What is BostonGene?
BostonGene operates at the intersection of artificial intelligence and clinical oncology, providing advanced molecular and immune profiling services. Its flagship BostonGene Tumor PortraitTM Tests offer a comprehensive analysis of the tumor microenvironment, identifying actionable mutations and biomarkers that dictate therapeutic response. By generating a personalized roadmap for cancer treatment, the company enables clinicians to move beyond one-size-fits-all protocols, effectively improving patient outcomes while optimizing healthcare economics. The firm's platform is designed to accelerate research and streamline the complex decision-making processes inherent in modern oncology.
How much funding has BostonGene raised?
BostonGene has raised a total of $200M across 2 funding rounds:
Series A
$50M
Series B
$150M
Series A (2019): $50M, investors not publicly disclosed
Series B (2022): $150M led by Impact Investment Capital, NEC Corporation, and Japan Industrial Partners
Key Investors in BostonGene
Japan Industrial Partners
Japan Industrial Partners, Inc. is an investment fund that supports the revitalization of businesses in Japan, providing capital and management support for corporate restructuring and growth.
Impact Investment Capital
An investment firm focused on deploying capital into high-growth enterprises that demonstrate significant potential for positive societal and economic impact.
NEC Corporation
A multinational information technology and electronics corporation that invests in innovative technologies to drive digital transformation and societal advancement.
What's next for BostonGene?
With the successful closure of its latest financing round, BostonGene is well-positioned to expand its clinical footprint and enhance its proprietary AI diagnostic engine. The company is expected to leverage this strategic backing to accelerate the adoption of its Tumor PortraitTM technology across global healthcare systems. Future growth initiatives will likely focus on deepening partnerships with pharmaceutical entities and expanding the utility of its molecular insights into broader therapeutic areas. As the industry shifts toward hyper-personalized medicine, BostonGene remains a critical player in defining the next generation of evidence-based cancer care.
See full BostonGene company page
